Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21.1 In 2020

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In